The Impact of Related Competitive Bidding Access Policy on the Use of Non-Exclusive Drugs in Public Hospitals
- VernacularTitle:竞价准入相关政策对公立医院非独家药品使用的影响
- Author:
Di FANG
1
;
Zheng ZHU
1
;
Li YANG
1
Author Information
1. 北京大学公共卫生学院 北京 100191
- Publication Type:Journal Article
- Keywords:
competitive bidding access;
non-exclusive drugs;
drug utilization;
interrupted time series analysis
- From:
Chinese Health Economics
2025;44(11):1-5
- CountryChina
- Language:Chinese
-
Abstract:
Objective:It aims to discuss the impact of the competitive bidding access policy on the use of non-exclusive drugs in public hospitals.Methods:A national hospital sales data-based interrupted time series analysis was performed,using Q2 2023 as the intervention point,to evaluate the bidding policy's impact on non-exclusive drugs' price,utilization volume,sales revenue,and daily cost.Results:(1)With the adjustment of medical insurance payment standards,the prices of non-exclusive drugs have generally decreased.(2)Following the implementation of the bidding policy,the usage of most drugs increased significantly,with only a few experiencing a decline.Sales amounts showed a divergent trend,with some decreasing due to market competition or clinical substitutes,and others increasing due to expanded demand.The overall decrease in daily expenses effectively reduced the burden on patients.Conclusion:The bidding access policy has effectively lowered drug prices through competition,driving notable consumption growth for heavily discounted products,while those with strong substitutes showed limited uptake.Meanwhile,sales revenue and daily costs varied significantly across drug categories.
